SABCS 2022 | TAKTIC: ipatasertib, endocrine therapy and CDK4/6i for patients with HR+/HER2- mBC

Seth Wander, MD, PhD, Massachusetts General Hospital, Boston, MA, discusses the results from the Phase I TAKTIC trial (NCT03959891) which evaluated combination therapy with the AKT inhibitor, ipatasertib, endocrine therapy and a CDK4/6 inhibitor for hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer (mBC). This combination approach was well tolerated in a heavily pre-treated population, with preliminary evidence of clinical efficacy. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.